RGX-104 RGX-104 is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
Targets
LXR
In vitro
RGX-104 is an oral first-in-class LXR agonist that robustly induces ApoE expression resulting in innate-immune mediated anti-tumor activity. RGX-104 drives anti-tumor immunity by regulating the abundance and activity of myeloid derived suppressor cells (MDSC) and dendritic cells (DC).
In vivo
Antitumor activity has been demonstrated with RGX-104 monotherapy in several syngeneic and xenograft tumor models, including melanoma, lung cancer, ovarian cancer, GBM and others. The anti-tumor activity of LXR-agonism is related to constitutive upregulation of ApoE expression.
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
External Descriptors
Not available
1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.
Utilizamos cookies para garantizar el correcto funcionamiento del sitio web y, cuando esté permitido, para mejorar su experiencia. Puede gestionar sus preferencias en cualquier momento en Configuración. Más información en nuestra Política de Cookies.
¿Quieres que te enviemos un mensaje cuando tengamos descuentos disponibles?
Recordármelo más tarde
¡Gracias! Por favor, revisa tu bandeja de entrada de correo electrónico para confirmar.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.